SLMMARVUsing (low cytometry. cellular IL-2 receptors were studied before and following chemoimmunotherapy combination in 20 patients with metastatic malignant melanoma (MMM). Patients received cisplatin (100 mg m") at days 1 and 28, recombinant IL-2 by continuous infusion from days 3 to 6, 17 to 21, 31 to 34, and 45 to 49. Interferon-alpha (IKNn) was given subcutaneously three times weekly. In terms of clinical response, we observed 55% objective response (complete: 15%), When pretreatment blood samples were compared with those of healthy donors, we did not observe any change in low (n chain) and high affinity receptor (a + ff) expression. In contrast, intermediate affinity p75 (3 chain) expression was decreased significantly (F ^ 00001) in MMM patients. During treatment, we found a dramatic increase oi ,i chain as well as high affinity (Q + J) expression in responding patients, as soon as IL-2 therapy began. Furthermore, the increase of ,i chain expression was limited to natural killer (NK) cells (CD56"). In non-responding patients, on the other hand, increase of both receptors was seen only at day 31. These data suggest the involvement of ;i chain expression in the mechanism of cell activation after chemoimmunotherapy. Moreover, this early 3 chain expression is correlated with the clinical response to chemoimmunotherapy.